Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lung cancer drug lorbrena under Post-Market safety review

NCT ID NCT03844464

First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 33 times

Summary

This completed study tracked 1290 lung cancer patients taking Lorbrena to see how often nervous system and liver side effects occur. Researchers aimed to identify factors that might increase these risks. The study does not test how well the drug works, only its safety in real-world use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • 3-22-7, Yoyogi, Shibuya-ku

    Tokyo, 151-8589, Japan

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Lorbrena (lorlatinib)

What this could lead to

If successful, this study could provide better understanding of Lorbrena's side effects, helping doctors manage them more safely.

What could go wrong

This is an observational study, not a test of whether Lorbrena works. It only looks at side effects, not effectiveness.

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.